Stock & Company Details
Anteris Technologies Global Corp. $AVR
Price:
N/A
N/A
97M
$874M
52 Week High:
N/A
10 Day Average Volume:
N/A
-3.95
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
N/A
AVR technical indicators
Latest Anteris Technologies Global Corp. (AVR) indicator readings as of 2026-08-28.
AVR's 14-day RSI is 46.8, in neutral territory. At $8.74 it is trading 29.3% above its 200-day moving average of $6.76, and below its 50-day average of $9.06. Price sits in the middle of its Bollinger Bands ($8.05 to $9.81). ADX reads 15.9, indicating a range-bound market rather than a trend.
Select a strategy to see its performance
Backtested on this stock over recent history.
| Strategy | Trend | Return | Win rate |
|---|---|---|---|
| MACD Momentum Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | – | – | |
| RSI Reversal Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | – | – | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | – | – | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | – | – |
Overview
Anteris Technologies Global Corp is a structural heart company committed to discovering, developing and commercializing innovative medical devices designed to improve the quality of life for patients with aortic stenosis. Its lead product, the DurAVR THV system, represents a unique product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
Finance Bot
Ask your questions
Start by typing a question below.
